Bioteque (ROCO:4107) Cyclically Adjusted Revenue per Share: NT$31.38 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4107 Bioteque Corp ROCO:4107
84 GF Score
Price NT$114.50
GF Value NT$126.11
Valuation Fairly Valued
View Full Analysis

What is Bioteque Cyclically Adjusted Revenue per Share?

Bioteque ROCO:4107 -0.87% 84 Cyclically Adjusted Revenue per Share is NT$31.38 as of Mar. 2026. GuruFocus rates ROCO:4107 with a GF Score™ of 84/100 and a GF Value™ of NT$126.11 (Fairly Valued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bioteque's adjusted revenue per share for the three months ended in Mar. 2026 was NT$7.840. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$31.38 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bioteque's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bioteque was 13.00% per year. The lowest was 7.20% per year. And the median was 11.50% per year.

As of today (2026-08-12), Bioteque's current stock price is NT$114.50. Bioteque's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$31.38. Bioteque's Cyclically Adjusted PS Ratio of today is 3.65.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bioteque was 8.88. The lowest was 3.63. And the median was 4.72.


Bioteque  (ROCO:4107) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bioteque's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=114.50/31.38
=3.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bioteque was 8.88. The lowest was 3.63. And the median was 4.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bioteque Cyclically Adjusted Revenue per Share Related Terms


Bioteque Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bioteque's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioteque Cyclically Adjusted Revenue per Share Chart

Bioteque Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.00 24.96 27.04 29.08 30.71

Bioteque Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.74 30.27 30.64 30.71 31.38

ROCO:4107 vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Bioteque's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioteque Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioteque's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bioteque's Cyclically Adjusted PS Ratio falls into.


ROCO:4107
84GF Score
Bioteque Corp ROCO:4107
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioteque Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bioteque's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=7.84/330.2130*330.2130
=7.840

Current CPI (Mar. 2026) = 330.2130.

Bioteque Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 5.280 241.018 7.234
201609 5.072 241.428 6.937
201612 4.804 241.432 6.571
201703 4.741 243.801 6.421
201706 5.024 244.955 6.773
201709 5.161 246.819 6.905
201712 5.514 246.524 7.386
201803 5.406 249.554 7.153
201806 5.866 251.989 7.687
201809 5.928 252.439 7.754
201812 5.978 251.233 7.857
201903 6.336 254.202 8.231
201906 6.806 256.143 8.774
201909 6.841 256.759 8.798
201912 6.743 256.974 8.665
202003 6.330 258.115 8.098
202006 6.761 257.797 8.660
202009 7.379 260.280 9.362
202012 7.550 260.474 9.571
202103 6.568 264.877 8.188
202106 6.367 271.696 7.738
202109 6.394 274.310 7.697
202112 6.946 278.802 8.227
202203 6.712 287.504 7.709
202206 7.016 296.311 7.819
202209 7.550 296.808 8.400
202212 7.634 296.797 8.494
202303 6.554 301.836 7.170
202306 6.813 305.109 7.374
202309 7.160 307.789 7.682
202312 7.433 306.746 8.002
202403 7.135 312.332 7.543
202406 7.457 314.175 7.838
202409 7.964 315.301 8.341
202412 7.219 315.605 7.553
202503 7.439 319.799 7.681
202506 7.641 322.561 7.822
202509 7.487 324.800 7.612
202512 8.100 324.054 8.254
202603 7.840 330.213 7.840

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$31.38 mean?
Bioteque (ROCO:4107) has a Cyclically Adjusted Revenue per Share of NT$31.38 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bioteque and its competitors.
Is Bioteque's Cyclically Adjusted Revenue per Share too high?
Bioteque's current Cyclically Adjusted Revenue per Share is NT$31.38. Overall, Bioteque has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Bioteque's Cyclically Adjusted Revenue per Share of NT$31.38 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bioteque and its competitors. Bioteque's current Cyclically Adjusted Revenue per Share is NT$31.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Fairly Valued. The stock's GF Value™ is NT$126.11, compared to a current price of NT$114.50 — trading 9.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$31.38. Bioteque's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current Cyclically Adjusted Revenue per Share is NT$31.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioteque (ROCO:4107) Overvalued in 2026?

Based on GuruFocus' analysis, Bioteque stock appears to be undervalued. The current stock price of NT$114.50 is trading 9.2% below its estimated GF Value™ of NT$126.11. GuruFocus considers Bioteque to be Fairly Valued.

Key valuation signals for ROCO:4107:

  • Cyclically Adjusted Revenue per Share: NT$31.38
  • GF Value™: NT$126.11 vs. price of NT$114.50 (9.2% below fair value)
  • GF Score™: 84/100

No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioteque Business Description

Address Chang-An E. Road, 5th Floor-6, No.23, Section 1, Taipei, TWN, 104
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
84GF Score

Get the complete analysis for ROCO:4107

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$114.50
Price
NT$126.11
GF Value